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Abstract 
Background: Variants of adiponutrin (PNPLA3) and adiponectin (ADIPOQ) genes 
were considered to be associated with non-alcoholic fatty liver disease (NAFLD). 
Although the prevalence of NAFLD is increasing, there are limited numbers of studies 
about the association in Indonesian population.  
Objective: To confirm that specific variants of PNPLA3 and ADIPOQ in Indonesian 
patients are associated with NAFLD.  
Methods: Data and DNA of 152 participants were obtained from a previous study in 
Dr. Kariadi Hospital, Semarang, Indonesia. PCR-RFLP analysis was performed for 
detection of PNPLA3 rs738409 and ADIPOQ rs2241767 variants. The diagnosis and 
severity of NAFLD were assessed according to NAFLD activity score (NAS) based 
on histopathology assessment of liver biopsy. 
Results: Allele G of PNPLA3 rs738409 was associated with NAFLD in both bivariate 
(p=0.009, OR 2.52, CI 95% 1.25–5.07) and multivariate (p=0.008, OR 2.62, CI 95% 
1.29%–5.32%) analysis, while ADIPOQ rs2241767 had no significant association. In 
NAFLD participants, both genotypes showed allele G was higher in the group of 
possible non-alcoholic steatohepatitis (NASH) – NASH (NAS >2) than in the simple 
steatosis group (NAS <2) i.e. 40.0% vs. 3.75% for the rs2241767 variant and 23.75% 
vs. 1.25% for the rs738409 variant, without significant association.  
Conclusion: Variant PNPLA3 rs738409 was associated with NAFLD incidence in 
studied population. Among NAFLD participants, the frequency of both variants were 
found higher in the possible NASH – NASH group, yet needs to be confirmed with 
more participants and a multicenter study. 
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  Non-alcoholic fatty liver disease (NAFLD) is the 
most common type of chronic liver injury in many 
countries.1 The prevalence of NAFLD increased 
variably from 9–40% in Asia and Western countries.1,2 
The spectrum of NAFLD ranges from slowly 
progressive simple hepatic steatosis to non-alcoholic 
steatohepatitis (NASH) and hepatic cirrhosis.  
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 NASH increases liver related mortality and is 
considered as a progressive liver disease. Approximately 
25-35% of NASH develops fibrosis and is more likely 
progressing to hepatic cirrhosis, hepatoma and liver 
failure.3–5 The NAFLD activity score (NAS) is 
commonly used to diagnose and grade NAFLD based on 
the histopathological assessment and is considered as the 
gold standard for NAFLD diagnosis. It could distinguish 
NASH from simple steatosis and predict the prognosis of 
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 The pathogenesis of NAFLD is explained as 
‘multiple parallel hits hypothesis’, in which insulin 
resistance, nutritional factors, gut microbiota, genetic, 
and epigenetic factors take part.9 There are candidates 
genes involved in the NAFLD pathogenesis, which 
includes gene encoding adiponutrin and adiponectin.10–
12 Adiponutrin, encoded by PNPLA3, has triacylglycerol 
lipase and acylglycerol O-acyltransferase activities that 
involve TAG hydrolysis and the acyl-CoA independent 
transacylation of acylglycerols,10 it maintains the 
triglyceride balance in the liver Variant PNPLA3 
rs738409 causes triglyceride accumulation in the liver, 
which accelerates the progression of NAFLD.13  
 Adiponectin, encoded by  ADIPOQ, has anti-
atherogenic, anti-diabetic and anti-inflammatory effects 
which is involved in pathogenesis of NAFLD.6,12,14 A 
systemic low adiponectin levels was associated with the 
development of NAFLD,15–17 and was considered as a 
diagnostic test severity of NAFLD.5,15 Variant ADIPOQ 
rs2241767 was reported as a risk factor of susceptibility 
and progression to NAFLD for it is involved in 
adiponectin dysregulation.3,18,19 However, the findings 
from previous studies on ADIPOQ rs2241767 variant 




 A previous study in Indonesian population reported 
that low level of adiponectin plasma was an independent 
risk factor for NAFLD incidence and severity,15 yet there 
was lack of data of the association of rs2241767 and 
rs738409 with NAFLD in this population. Since the 
prevalence of NAFLD in Indonesia is considered high, 
further research of these variants is needed. This study 
aimed to confirm whether PNPLA3 rs738409 and 
ADIPOQ rs2241767 variants are associated with NAFLD 
in Indonesian patients.  
 
MATERIALS AND METHODS  
 A total of 152 participants were included in this study, 
80 patients with NAFLD and 72 were controls. The 
inclusion criteria of case and control group were listed in 
the previous study.15 Participants were classified as 
NAFLD according to NAS as per NASH Clinical 
Research Network (NASH CRN) system based on 
histopathology of liver. Score of NAS <2 indicates 
‘simple steatosis’ or ‘no NASH’, score 3–4 indicates 
‘possible NASH’, and score >5 is indicating ‘NASH’.20  
 Participants were Indonesian patients, predominantly 
Javanese. Liver biopsy procedures and other data 
collections were done at the Dr. Kariadi Hospital 
Semarang. DNA was obtained from a previous study that 
used salting out method,15 while the genotyping was 
analysed at the Center for Biomedical Research of 
Universitas Diponegoro. This study was approved by the 
Human Research Ethics Committee of the Faculty of 
Medicine Universitas Diponegoro–Dr. Kariadi Hospital 
Semarang (No.128/EC/FK- RSDK/2014).  
 The ADIPOQ rs2241767 variant (A > G) and 
PNPLA3 rs738409 variant (C > G) were genotyped by 
polymerase chain reaction - restriction fragment length 
polymorphism (PCR-RFLP) method according to Li et al 
and Islek et al.3,21 The PCR reaction for determination of 
rs2241767 was pre-degenerated at 94°C for 5 min, 
followed by 35 cycles of denaturation at 94°C for 30 s, 
annealing at 60°C for 30 s, elongation at 72°C for 30 s, 
final elongation at 72°C for 10 min, and the PCR reaction 
for determination of rs738409 was pre-degeneration at 
95°C for 5 min, followed by 35 cycles of denaturation at 
95°C for 60 s, annealing at 58°C for 30 s, elongation at 
72°C for 60 s, final elongation at 72°C for 10 min. The 
primers were purchased from IDT (Singapore), while 
restriction enzymes were from NEB (Ipswich, MA, 
USA). PCR reagent for DNA optimation was MyTaq 
Mix (Bioline, Singapore). The PCR products were run on 
1.5% agarose gels electrophoresis containing 0.1% 
FloroSafe DNA Stain (1st Base, Singapore) and was 
analyzed using Gel Doc (Bio-Rad Laboratories, USA). 
PCR method of rs2241767 showed a 292 bp product of 
AA genotype, two fragments of 163 and 129 bp product 
of GG genotype, and three fragments of 292 bp in 
heterozygous (A/G) genotype participants. PCR method 
of rs738409 showed a 139 bp product of CC genotype, 
two fragments of 112 and 27 bp products of GG 
genotype, and three fragments of 139 bp in heterozygous 
(C/G) genotype participants. The details of primers, 
enzymes, PCR product and fragment lengths were shown 




Figure 1. Electrophoresis of Restriction Fragments. PCR 
product of PNPLA3 rs738409 was cut into 112 bp and 27 
bp fragments (a). While PCR product of ADIPOQ 
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 To analyze the equilibrium and errors in genotyping, 
Hardy-Weinberg Equilibrium Test was done for both 
rs738409 and rs2441767. Bivariate and multivariate 
analyses of the correlation between genotype and 
NAFLD were done using SPSS software version 20.0 
(Polar Engineering and Consulting, USA). The age of 
participants was categorized into 3 groups; age 20–40, 
age 41–60, and age more than 60 years old. To analyse 
the correlation between genotype and NAFLD severity; 
simple steatosis, possible NASH, and control 
participants were sorted as non-NASH. Simple steatosis 
and possible NASH participants were sorted as NAFLD 
non-NASH. Differences with a p value of <0.05 were 
considered statistically significant. 
 
RESULTS  
 The age of NAFLD participants ranged from 23 to 74 
years old with a mean age of 45.52 (1.16) years, while 
control participants ranged from 20 to 72 years old with 
a mean age of 44.54 (1.18) years. The result of Hardy-
Weinberg Equilibrium test for both rs738409 and 
rs2441767 showed no significant different (p=0.85 and 
Table 1. Primers, Enzymes, and PCR Product and Fragment Lengths  
Variant Primer Enzyme 
PCR Product 
(bp) 
Fragment Length (bp) 
rs2241767 F: GGTGAGAAGGGTGAGAAAGGAG Bsu36I 292 163 + 129 
 R: TACTGGGAATAGGGATGAGGG    
rs738409 F: CCCTGCTCACTTGGAGAAAG NlaIII 139 112 + 27 
 R: AGGAGGGATAAGGCCACTGT    
 
Table 2. Genotype Distribution of rs2241767 and rs738409 Based on Gender  
rs2241767  rs738409 
Genotypes (%) Alleles (%)  Genotypes (%) Alleles (%) 
 AA AG GG A G CC CG GG C G 
Total (n=152)          
NAFLD 60 (75.0) 19 (23.8) 1 (1.3) 139 (86.9) 21 (13.1) 45 (56.2) 32 (40.0) 3 (3.8) 122 (76.2) 38 (23.8) 
Control 48 (66.7) 24 (33.3) 0 (0.0) 120 (83.3) 24 (16.7) 55 (76.4) 15 (20.8) 2 (2.8) 125 (86.8) 19 (13.2) 
Men (n=84)           
NAFLD 37 (75.5) 12 (24.5) 0 (0.0) 86 (87.8) 12 (12.2) 30 (61.2) 17 (34.7) 2 (4.1) 77 (78.6) 21 (21.4) 
Control 21 (60.0) 14 (40.0) 0 (0.0) 56 (80.0) 14 (20.0) 28 (80.0) 7 (20.0) 0 (0.0) 63 (90.0) 7 (10.0) 
Women (n=68)          
NAFLD 23 (74.2) 7 (22.6) 1 (3.2) 53 (85.5) 9 (14.5) 15 (48.4) 15 (48.4) 1 (3.2) 45 (72.6) 17 (27.4) 
Control 27 (73.0) 10 (27.0) 0 (0.0) 64 (86.5) 10 (13.5) 27 (72.9) 8 (21.6) 2 (5.4) 62 (83.8) 12 (16.2) 
 
Table 3. Bivariate Analysis of rs2241767 and rs738409  
 
rs2241767 rs738409 
AG+GG AA P OR (CI95%) CG+GG CC P 
OR 
(CI95%) 
Group         
Case  20 60 0.26 0.67 35 45 0.009 2.52 
Control 24 48  (0.33-1.35) 17 55  (1.25-5.07) 
Gender         
Men 26 58 0.55 1.25 26 58 0.39 0.72 
Women  18 50  (0.61-2.53) 26 42  (0.37-1.42) 
Age          
20-40 17 34  Reference 15 36  Reference 
41-60 26 66 0.53 0.79 
(0.38-1.65) 
34 58 0.36 1.41 
(0.67-2.94) 
>60 1 8 0.21 0.25 
(0.03-2.16) 
3 6 0.81 1.20 
(0.26-5.44) 
Severity 1          
Simple Steatosis 1 10  Reference 3 8  Reference 
Possible NASH 9 31 0.34 2.90 
(0.37-25.82) 
20 20 0.19 2.67 
(0,62-11.54) 
NASH 10 19 0.14 5.26 
(0.59-47.20) 
12 17 0.41 1.88 
(0.41-8.60) 
Severity 2         
NASH 10 19 0.30 1.38 12 17 0.24 1.46 
Non NASH 34 89  (0.59-3.26) 40 83  (0.64-3.36) 
Severity 3         
NASH 10 19 0.18 0.46 12 17 0.47 1.16 
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p=0.71, respectively). Electrophoresis of restriction 
fragments of both variants is shown in Figure 1. The 
frequency of both genotypes is summarized in Table 2. 
 Allele G in rs2241767 was found higher in men and 
in the group of 20-40 years old (30.95% and 33.33%, 
respectively), while allele G in rs738409 was found 
higher in women and in the group of 41-60 years old 
(38.24% and 36.96%, respectively), despite no 
statistically significant association. A significant 
association was identified between variant rs738409 and 
NAFLD (p=0.009, OR 2.52, CI 95% 1.25-5.07) (Table 
3). In NAFLD participants, both genotypes showed 
allele G was found higher in the group of possible NASH 
– NASH (NAS >2) than in the simple steatosis group 
(NAS <2) (40.0% vs. 3.75% for rs2241767 variant and 
23.75% vs. 1.25% for rs738409 variant), without 
significant association (p>0.05). In multivariate 
analysis, there was significant association between 
variant rs738409 and NAFLD (p=0.008, OR 2.62, CI 
95% 1.29% - 5.32%) (Table 4).  
 
DISCUSSION  
 Variants in certain genes were reported to play a role 
in NAFLD occurrence and severity.5,6 A previous study 
documented that metabolic syndrome, insulin resistance, 
and low adiponectin levels were independent risk factors 
for the incidence of NAFLD. 15 By observing the same 
participants, this study analyzed the data including the 
severity degree of NAFLD confirmed by liver biopsy, 
and PNPLA3 and ADIPOQ variants as susceptibility 
factors for NAFLD and NASH. 5,6 To the best of our 
knowledge this is the first study in Indonesia with 
predominantly Javanese population. 
 Previous studies showed a significant association 
between ADIPOQ rs2241767 and NAFLD.3,19 This 
current study noted that the allele G of variant ADIPOQ 
rs2241767 was found in 13.1% NAFLD participants in 
Semarang, Indonesia. Variant rs2241767 is an intron 
variant22 which can influence gene expression in various 
ways, including mechanisms through splicing, 
transcription, polyadenylation,  mRNA  export,  
translation, and specific features that boost expression.  
Nevertheless, which predominate intron mechanism 
enhances or represses the expression of a gene is not yet 
known.23 The mechanism of allele G of ADIPOQ 
rs2441767 in adiponectin dysregulation is also not 
clearly understood, although there are studies reporting 
positive effect of this variant and NAFLD.3,19  
 The PNPLA3 rs738409 variant increases the risk of 
development and progression of NAFLD.24,25 Consistent 
with previous findings, variant PNPLA3 rs738409 in this 
study showed significant association with NAFLD 
incidence (p=0.009, OR 2.52, CI 95% 1.25-5.07). 
 This study found a higher frequency of allele G in 
ADIPOQ rs2241767 in men and in the group of 20-40 
years old, while allele G in PNPLA3 rs738409 was found 
higher in women and in the group of 41-60 years old, 
despite no significant association (p>0.05). It confirmed 
that sex is one of the NAFLD risk factors. Higher 
prevalence NAFLD rates were seen in men younger than 
menopause age in women. After menopause, the risk 
becomes comparable between both sexes, perhaps due to 
the effects of estrogen.26,27 However, whether the age 
factor could affect the impact of variant PNPLA3 on 
NAFLD prevalence is still unclear, as NAFLD could start 
since childhood.28,29 
 In this study, allele G of both variants was found 
higher in NASH participants, despite no statistically 
significant association (p>0.05). Previous results noted 
an association between variant PNPLA3 rs738409 and 
NASH susceptibility,30,31 The PNPLA3 rs738409 allele 
was associated with adipocytes and increased leptin 
transcription in participants with NAFLD. Therefore, the 
adipose tissue endocrine modulation activity may be 
involved in mechanism of NASH susceptibility induced 
by PNPLA3.24 On the other side, the association between 
variant ADIPOQ rs2241767 and NASH has not been 
reported. The factors behind the association between 
ADIPOQ rs2241767 and NASH remain unclear. It is not 
known yet whether homozygous or heterozygous alleles 
are involved in development of NAFLD, although this 
study documented higher heterozygous allele frequency 
in NAFLD participants. 
 By multivariate analysis, only variant rs738409 was 
found significantly associated with NAFLD (p=0.008, 
OR 2.62, CI 95% 1.29% - 5.32%). However, both 
genotypes showed allele G was found higher in group of 
possible NASH – NASH than in simple steatosis group, 
despite no significant association (p>0.05). Interestingly, 
there was a study documented PNPLA3 rs738409 variant 
represented a genetic determinant of serum adiponectin 
levels.24 Since systemic adiponectin levels considered 
involved in development of NAFLD15–17 and variant 
ADIPOQ rs2241767 associated with risk of NAFLD,3,4,6 
further study is needed to confirm the findings. The 
potential limitation of this study is the relatively small 
sample size, therefore larger sample sizes and diverse 




 In line with ‘multiple parallel hits pathogenesis’ of 
NAFLD, there are many variations of candidate genes 
which are considered related to NAFLD and its severity. 
Two suspected spots of genes considered involved in 
NAFLD development were observed in this study. As far 
as we know, this is the first study in Indonesia and 
confirmed the association between PNPLA3 rs738409 
and NAFLD in Indonesian participants. However, other 
spots and other genes are needed to be observed, as well 
as their association with clinical findings. As Indonesia 
has lots of ethnicities, a multicenter study is needed to 
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